Paul Healy: AstraZeneca and Daiichi Sankyo have announced positive results from datopotamab deruxtecan in certain lung cancer patients
Paul Healy, Director of PHARMeMED, shared on LinkedIn:
“AstraZeneca (AZ) and Daiichi Sankyo have announced positive results from a late-stage study of their investigational TROP2-targeting antibody drug conjugate, datopotamab deruxtecan, in certain lung cancer patients.
The phase 3 TROPION-Lung01 trial has been evaluating the efficacy and safety of the drug versus the current standard of care chemotherapy, docetaxel, in patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who require systemic therapy following prior treatment.
Recognised as the most common type of lung cancer, which was estimated to affect nearly 2.2 million people globally in 2022, NSCLC accounts for around 80% of all cases.
Results from the study showed that datopotamab deruxtecan demonstrated a clinically meaningful overall survival improvement in patients compared to docetaxel and maintained a safety profile that was consistent with previous analysis, with no new safety concerns identified, but did not reach statistical significance.
Susan Galbraith, executive vice president, oncology research and development (R and D), AZ, commented: ‘These results reinforce the potential for datopotamab deruxtecan to replace conventional chemotherapy in this late-line setting and underscore our confidence in ongoing trials evaluating this therapy in first-line lung cancer.’
Ken Takeshita, global head, R and D, Daiichi Sankyo, said: ‘This data will support our ongoing discussions with regulatory authorities globally to potentially bring datopotamab deruxtecan to patients as quickly as possible and mark another step forward in creating new standards of care for patients with cancer.’
The new results build on the positive progression-free survival (PFS) results, which were announced last year and presented at the 2023 European Society for Medical Oncology Congress.
The results demonstrated that datopotamab deruxtecan showed a statistically significant improvement in PFS and a clinically meaningful PFS benefit compared to chemotherapy in patients with non-squamous NSCLC.
Source: Paul Healy/LinkedIn